After a tough year for many in biopharma, what’s the outlook for 2023? Evaluate Vantage’s preview sets out the projects waiting in the wings that could drive some much-needed positivity, the drugs and companies set to grow the sector’s top line, and the key clinical catalysts ahead.
The report also includes new analyses of data from 2022 to set the context for what lies ahead, and for the first time includes a poll of 150 industry experts, with their views on the outlook for the stock market, IPOs and M&A. Packed with insights on innovation, regulation and more, download your free copy here.
.
WE'LL LOOK AT:
What will be 2023’s top-selling drug?
Which new diabetes drug will be one of 2023’s fastest growers?
Which Alzheimer’s antibodies will feature among 2023’s biggest approval decisions?
What will be some of 2023’s closely watched research projects?
Has the IPO market finally bottomed out?
Which companies are next year’s potential bid targets?
